

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8 (Canceled).

Claim 9 (New): A pharmaceutical composition comprising N-acetylcysteine and fosfomycin, wherein said pharmaceutical composition is capable of inhibiting or disrupting one or more biofilms produced by one or more pathogens of the urinary tract.

Claim 10 (New): The pharmaceutical composition as claimed in claim 9, wherein said one or more pathogens is *Escherichia coli*.

Claim 11 (New): The pharmaceutical composition as claimed in claim 9, wherein said fosfomycin is in the form of a sodium salt or trihydroxymethylaminomethane salt.

Claim 12 (New): A method of inhibiting or disrupting one or more biofilms produced by one or more pathogens of the urinary tract, said method comprising:
administering fosfomycin to a patient in need thereof in an amount effective to inhibit or disrupt one or more biofilms produced by one or more pathogens of the urinary tract.

Claim 13 (New): The method as claimed in claim 12, wherein said fosfomycin is administered in an amount of 200 to 3000 mg/day.

Claim 14 (New): The method as claimed in claim 12, further comprising administering N-acetylcysteine.

Claim 15 (New): The method as claimed in claim 14, wherein said N-acetylcysteine is administered in an amount of 128 to 2000 mg/day.

Claim 16 (New): The method as claimed in claim 12, wherein said one or more pathogens is *Escherichia coli*.

Claim 17 (New): The method as claimed in claim 12, wherein said fosfomycin is in the form of a sodium salt or trihydroxymethylaminomethane salt.

Claim 18 (New): A process for preparing a pharmaceutical composition, said process comprising:

preparing said pharmaceutical composition which comprises fosfomycin in a form suitable for injection or for oral administration.

Claim 19 (New): The process as claimed in claim 18, wherein said pharmaceutical composition is capable of inhibiting or disrupting one or more biofilms produced by one or more pathogens of the urinary tract.

Claim 20 (New): The process as claimed in claim 18, wherein said pharmaceutical composition further comprises N-acetylcysteine.

Claim 21 (New): The process as claimed in claim 18, wherein said one or more pathogens is *Escherichia coli*.

Claim 22 (New): The process as claimed in claim 18, wherein said fosfomycin is in the form of a sodium salt or trihydroxymethylaminomethane salt.